Luvometinib clinical trials
Also written FCN-159.
How each study uses luvometinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the luvometinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
13 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 7
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (6) · Beijing Tiantan Hospital (2) · West China Second University Hospital (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Xuanwu Hospital, Beijing (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test luvometinib, phase 3 first.
- Apr 2027FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF AlterationPhase 3 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Studies
Open first, then newest update. How each study uses luvometinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLCRecruitingPhase 2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07562581Written as luvometinib + anlotinib
- Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell HistiocytosisNot yet recruitingPhase 2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07728201Written as Luvometinib
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingPhase 2Beijing Tiantan HospitalNCT07713745Written as Luvometinib
- Luvometinib in Combination With Serplulimab for NF2-Related TumorsNot yet recruitingPhase 1/2Beijing Tiantan HospitalNCT07708285Written as Luvometinib
- Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisRecruitingNot applicableWest China Second University HospitalNCT07431060Written as Luvometinib
- Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsRecruitingNot applicableWest China Second University HospitalNCT07371182Written as Luvometinib
- Phase II Study of FCN-159 in NF2 Nerve Sheath TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06553365Written as FCN-159
- Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1Not yet recruitingPhase 1/2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07024394Written as Luvometinib Tablets
- FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF AlterationNot yet recruitingPhase 3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07004075Written as Luvometinib
- An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous MalformationsRecruitingPhase 2Xuanwu Hospital, BeijingNCT06913725Written as FCN-159
- To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCHRecruitingPhase 2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT05997602Written as FCN-159
- FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasActive, not recruitingPhase 3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT05913037Written as Test group (Group A): FCN-159 8 mg, orally, once daily;
- Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1Active, not recruitingPhase 1/2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT04954001Written as FCN-159
Codes
What other systems call luvometinib · ClinicalTrials.gg INT016057
- UNII (FDA) B2DYT4V89XLUVOMETINIBConfirmed FDA, Wikidata
- Wikidata Q135746264luvometinibConfirmed FDA, Wikidata
- NCI Thesaurus C172382LuvometinibOne source FDA
- DrugBank DB21696One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B2DYT4V89X | LUVOMETINIB | Confirmed FDA, Wikidata |
| Wikidata | Q135746264 | luvometinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C172382 | Luvometinib | One source FDA |
| DrugBank | DB21696 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.